Thompson Siegel & Walmsley LLC Grows Stake in QuidelOrtho Co. (NASDAQ:QDEL)

Thompson Siegel & Walmsley LLC boosted its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 33.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 337,860 shares of the company's stock after buying an additional 85,405 shares during the quarter. Thompson Siegel & Walmsley LLC owned approximately 0.50% of QuidelOrtho worth $15,052,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. grew its holdings in QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock worth $58,000 after purchasing an additional 844 shares during the last quarter. Spire Wealth Management purchased a new position in QuidelOrtho in the fourth quarter worth $74,000. KBC Group NV grew its holdings in QuidelOrtho by 122.9% in the fourth quarter. KBC Group NV now owns 3,437 shares of the company's stock worth $153,000 after purchasing an additional 1,895 shares during the last quarter. Captrust Financial Advisors purchased a new position in QuidelOrtho in the third quarter worth $238,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of QuidelOrtho during the third quarter worth $262,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Citigroup upgraded shares of QuidelOrtho from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $44.00 to $50.00 in a research note on Wednesday, December 11th. UBS Group lifted their price objective on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a research note on Thursday, February 13th. Royal Bank of Canada lowered their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research note on Thursday, February 13th. William Blair reiterated a "market perform" rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. Finally, StockNews.com downgraded shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $51.20.

Remove Ads

QuidelOrtho Stock Performance

NASDAQ QDEL traded up $0.08 on Monday, reaching $36.20. 1,071,425 shares of the company's stock traded hands, compared to its average volume of 926,997. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -1.20 and a beta of 0.10. The stock has a 50 day moving average price of $41.89 and a 200-day moving average price of $41.94. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $49.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities research analysts predict that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.